Skip to content
Cart

Lipoprotein(a)

The genetic risk factor many men overlook

Lipoprotein(a) or Lp(a) is a genetically determined fat particle in the blood that is structurally similar to LDL cholesterol but contains additional factors that affect vascular health and blood clotting. Approximately 20–30% of the world's population has elevated levels—regardless of diet, exercise, or other risk factors. A high Lp(a) level is considered an independent risk factor for heart attack, stroke, aortic valve calcification, and peripheral vascular disease.

Lp(a) tends to accumulate in atherosclerotic plaques and increases inflammation and the tendency to clot—especially in men with a family history or early cardiovascular disease.

Because Lp(a) levels are largely determined by genetics, they are barely affected by lifestyle. Nevertheless, knowing the level is crucial—not to cause panic, but to enable targeted prevention and risk assessment.

Typical Values and Their Significance

  • < 30 mg/dL (< 75 nmol/L) - low risk
  • 30–50 mg/dL (75–125 nmol/L) - moderately elevated; should be monitored depending on other risk factors
  • ≥ 50 mg/dL (125 nmol/L) - clearly elevated risk of cardiovascular disease

These thresholds are guidelines—in individual cases, the personal risk profile may also be relevant even with moderate Lp(a).

Why Lp(a) Is Important for Men

Many men feel healthy but still have elevated Lp(a) levels—they often do not recognize the connection. The result: The risk only becomes apparent after a heart attack or stroke.

Lp(a) increases, in particular:

  • the risk of vascular blockages and blood clots
  • the progression of atherosclerosis
  • the risk of aortic valve calcification
  • the risk of cardiovascular events despite supposedly "normal" cholesterol levels

A positive result does not necessarily mean that treatment is required, but it helps to more consciously assess the burden caused by LDL, inflammation, and metabolic disorders.

Diagnosis and Assessment of Lp(a)

A simple blood test measures the Lp(a) level. Because it is genetically determined, a single measurement is often sufficient—especially if no major fluctuations due to lifestyle changes are expected.

Recommendations:

  • Lp(a) in cases of family history of heart disease or early heart attacks
  • Lp(a) measurement in cases of elevated LDL, lipid profile, or risk despite a healthy lifestyle
  • Interpretation in the context of other markers such as LDL, HDL, ApoB, and CRP

What to Do if Lp(a) Is Elevated

Because the level is not directly influenced by diet or exercise, other strategies are prioritized:

  • Monitoring and, if necessary, lowering LDL & triglycerides
  • Reducing inflammation (measurable, for example, via the CRP level)
  • Monitoring blood pressure, blood sugar, and insulin sensitivity
  • for very high risk: lipid apheresis (covered by insurance in selected cases)
  • Future: clinical trials for pharmacological Lp(a) reduction are underway

Conclusion

Lp(a) is a genetic risk marker that is highly important for men—especially in combination with other risk factors. An elevated level does not necessarily mean disease, but it does offer opportunities for prevention: awareness, monitoring of other lipid and inflammatory levels, and targeted medical guidance.

Tip: In the podcast episode "What Your Blood Values Really Mean", Dr. Jonathan Apasu and Dr. Helena Orfanos‑Böckel analyze a comprehensive blood panel, including lipid profiles, ApoB, and Lp(a). The episode impressively demonstrates how precise diagnostics and individual interpretation go hand in hand—even when lifestyle appears perfect.

 

Podcast episode: "Blood Values 101" with Dr. Helena Orfanos-Boeckel on "Men

You can have your Lp(a) level measured by your family doctor, at a direct laboratory, or through our Comprehensive Health Check at Home.

 

 

Sources

  1. Nordestgaard, B. G., Langsted, A. (2016). Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. Journal of Lipid Research, 57(11), 1953–1975. https://doi.org/10.1194/jlr.R071233
  2. Kronenberg, F., Mora, S., Stroes, E. S. G. et al. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal, 43(39), 3925–3946. https://doi.org/10.1093/eurheartj/ehac361
  3. Erqou, S. et al. (2009). Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 302(4), 412–423. https://doi.org/10.1001/jama.2009.1063
  4. Tsimikas, S. (2017). A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. Journal of the American College of Cardiology, 69(6), 692–711. https://doi.org/10.1016/j.jacc.2016.11.042
  5. Pare, G., Bhatt, D. L., Giesecke, C. (2023). Lipoprotein(a): a genetically determined risk factor for cardiovascular disease. Critical Reviews in Clinical Laboratory Sciences, 60(8), 560–572. https://doi.org/10.1080/10408363.2023.2229915